Calls
1
u/Ok-Tomato261
Reddit r/ValueInvesting
Win Rate
0.0%
return
-93.9%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Feb 07
$16.38
-93.9%
The author is long Diamyd Medical (DMYD B) ahead of Phase 3 topline results due in March 2026, arguing that positive data could support an Accelerated Approval/BLA filing and drive a +100–300% gap up or attract a buyout at a premium. The causal mechanism is binary clinical data in a precision-medicine subgroup (HLA DR3-DQ2), with valuation support from Sanofi's $2.9B purchase of competitor Provention Bio/Tzield versus Diamyd's ~$200M market cap. The author states the main risk is that bad data sends the stock down -80% to cash value.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/Ok-Tomato261 has 1 trade ideas tracked on Buzzberg across 1 tickers since February 2026. Most covered: DMYD-B.ST.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
